Szu-Chin (George) Fu
Cited by
Cited by
MitoFates: improved prediction of mitochondrial targeting sequences and their cleavage sites*[S]
Y Fukasawa, J Tsuji, SC Fu, K Tomii, P Horton, K Imai
Molecular & Cellular Proteomics 14 (4), 1113-1126, 2015
Bi-3406, a potent and selective sos1–kras interaction inhibitor, is effective in kras-driven cancers through combined mek inhibition
MH Hofmann, M Gmachl, J Ramharter, F Savarese, D Gerlach, ...
Cancer Discovery 11 (1), 142-157, 2021
LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins
D Xu, K Marquis, J Pei, SC Fu, T Cağatay, NV Grishin, YM Chook
Bioinformatics 31 (9), 1357-1365, 2015
ValidNESs: a database of validated leucine-rich nuclear export signals
SC Fu, HC Huang, P Horton, HF Juan
Nucleic acids research 41 (D1), D338-D343, 2013
Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals
HYJ Fung, SC Fu, YM Chook
elife 6, e23961, 2017
Structural determinants of nuclear export signal orientation in binding to exportin CRM1
HYJ Fung, SC Fu, CA Brautigam, YM Chook
elife 4, e10034, 2015
Prediction of leucine-rich nuclear export signal containing proteins with NESsential
SC Fu, K Imai, P Horton
Nucleic acids research 39 (16), e111-e111, 2011
Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma
K Raghav, S Liu, MJ Overman, AF Willett, M Knafl, SC Fu, A Malpica, ...
Cancer discovery 11 (11), 2738-2747, 2021
Correlation of CRM1-NES affinity with nuclear export activity
SC Fu, HYJ Fung, T Cağatay, J Baumhardt, YM Chook
Molecular biology of the cell 29 (17), 2037-2044, 2018
BI-3406 and BI 1701963: Potent and selective SOS1:: KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan
D Gerlach, M Gmachl, J Ramharter, J Teh, SC Fu, F Trapani, D Kessler, ...
Cancer research 80 (16_Supplement), 1091-1091, 2020
Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial
DM Halperin, S Liu, A Dasari, D Fogelman, P Bhosale, A Mahvash, ...
JAMA oncology 8 (6), 904-909, 2022
ScreenCap3: Improving prediction of caspase‐3 cleavage sites using experimentally verified noncleavage sites
SC Fu, K Imai, T Sawasaki, K Tomii
Proteomics 14 (17-18), 2042-2046, 2014
Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1:: KRAS inhibitor opens a new approach for treating KRAS-driven tumors
MH Hofmann, M Gmachl, J Ramharter, F Savarese, D Gerlach, ...
Molecular Cancer Therapeutics 18 (12_Supplement), PL06-01-PL06-01, 2019
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov 11, 142–157, doi: 10.1158 …
MH Hofmann, M Gmachl, J Ramharter, F Savarese, D Gerlach, ...
CD-20-0142, 2021
Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).
LO Chapman, MJ Overman, A Willett, M Knafl, SC Fu, A Malpica, C Scally, ...
Journal of Clinical Oncology 39 (15_suppl), 8557-8557, 2021
Mitochondrial protein cleavage site predictor
Y Fukasawa, R Wan, SC Fu, J Tsuji, N Sakiyama, K Imai, P Horton
2010 IEEE International Conference on Bioinformatics and Biomedicine …, 2010
Genome informatics: advances in theory and practice
S Fu, P Horton
Genome Medicine 2, 1-2, 2010
2P-241 Sequence Analysis of Nuclear Export Signals (Bioinformatics: Functional genomics, The 47th Annual Meeting of the Biophysical Society of Japan)
SC Fu, P Horton
Seibutsu Butsuri 49 (supplement), S144-S145, 2009
2P-241 核外移行シグナルの配列解析 (生命情報科学-機能ゲノミクス, 第 47 回日本生物物理学会年会)
F Szu-Chin, H Paul
生物物理 49 (supplement), S144-S145, 2009
MoiraiSP: a novel mitochondrial cleavage site predictor
Y Fukasawa, SC Fu, J Tsuji, N Sakiyama, K Imai, P Horton
The system can't perform the operation now. Try again later.
Articles 1–20